SWOG clinical trial number
CTSU/EA2186

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Closed
Phase
Abbreviated Title
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer …
Activated
06/18/2020
Closed
10/17/2023

Research committees

Gastrointestinal Cancer

Treatment

5-Fluorouracil Gemcitabine hydrochloride Leucovorin Calcium Liposomal Doxorubicin Nab-Paclitaxel

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unity (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2025

Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT) - A randomized phase II study of Gemcitabine and NabPaclitaxel compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (NCT04233866)

E Dotan;P Catalano;L Lenchik;R Boutin;X Yao;J Ohr;K Lim;G Fisher;N Vijayvergia;S Chandana;A Kalyan;R Dunne;D Zhen;D Li;K Reiss;M Simon;J Berlin;L Waggoner;P O'Dwyer ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)

2022

EA-2186: A randomized phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5- Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment naïve metastatic pancreatic cancer (GIANT): Trials in Progress

E Dotan;P Catalano;L Lenchik;R Boutin;X Yao;C Gatsonis;D Zhen;D Li;L Wagner;M Simon;T Wong;P O'Dwyer J Clin Oncol 40, 2022 (suppl 16; abstr TPS4185), poster 157B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
54%
Open
Phase